Antengene Prepares for Major Presentation on ATG-022 at ESMO
Leading biopharmaceutical company Antengene Corporation Limited, known for its innovative approach, is making waves in the oncology community with its latest announcement related to ATG-022, a Claudin 18.2 antibody-drug conjugate (ADC). The company has revealed that an abstract showcasing significant findings from its ongoing Phase I/II study will be presented as a poster at the upcoming European Society for Medical Oncology Annual Congress, ESMO 2025.
Exciting Developments at ESMO 2025
The presentation features compelling data on ATG-022, a therapy crafted to target cancer cells expressing the protein Claudin 18.2. This critical event will take place from October 17 to October 21 at the Messe Berlin, a notable venue that hosts cutting-edge medical discussions. ATG-022's acceptance for presentation underscores the increasing recognition of its potential in transforming cancer treatment.
Overview of the ATG-022 Study
The study, titled "Phase I/II Study of Claudin 18.2 ADC ATG-022 in Patients with Advanced Gastric/Gastroesophageal Junction Cancer (CLINCH)," will include insights from abstract number 2907 and presentation number 2113P, set for October 19, 2025. This focus on multiple cancer types with varying levels of CLDN18.2 expression provides a deep dive into how this innovative treatment could benefit patients across the board.
About the Claudin 18.2 Target
Claudins, including Claudin 18.2, play essential roles in cell junction integrity and permeability. Unfortunately, these proteins can become aberrantly expressed in various cancers, including gastric, cholangiocarcinoma, and pancreatic cancers. ATG-022 aims to capitalize on this anomaly, effectively targeting and treating tumors characterized by high expression of Claudin 18.2. This unique targeting strategy places ATG-022 at the forefront of targeted cancer therapies.
Robust Efficacy Observed in Clinical Trials
Results from the ongoing CLINCH study illustrate the robust efficacy of ATG-022, which appears to work effectively at various expression levels of CLDN18.2 in gastric cancer patients. The availability of such a broad spectrum of efficacy opens up new possibilities for treating a greater number of patients with positive expressions of this biomarker.
Promise Beyond Gastric Cancer
What’s particularly exciting is ATG-022's performance in patients with low CLDN18.2 expression, hinting at the potential for broader applications beyond gastric cancer. This adaptability could provide new options for healthcare providers and patients alike, especially for those whose tumors fall within similar expression profiles.
About Antengene Corporation Limited
Antengene Corporation Limited, operating under the stock ticker SEHK: 6996.HK, embodies a strong commitment to pioneering biopharmaceutical advancements that transcend borders in cancer treatment. With a portfolio that entails nine oncology assets at varying stages—ranging from clinical to commercial—the company is making meaningful strides in the market.
Currently, Antengene has secured 31 investigational new drug (IND) approvals across various regions. Their proactive approach to securing new drug applications (NDAs) in multiple Asia Pacific markets reflects a deep understanding of the global oncology landscape, including successful approvals for therapies such as XPOVIO.
Frequently Asked Questions
What is ATG-022?
ATG-022 is an antibody-drug conjugate designed to target cancers expressing Claudin 18.2, showing promising efficacy across various expressions in clinical studies.
When will the presentation at ESMO 2025 occur?
The poster presentation for ATG-022 is scheduled for October 19, 2025, during the ESMO 2025 conference taking place in Berlin.
Why is this presentation important?
This event marks a significant opportunity for Antengene to share groundbreaking findings concerning ATG-022's efficacy in treating cancers linked to Claudin 18.2.
What other therapies is Antengene developing?
Antengene currently has nine oncology assets in its pipeline, emphasizing its commitment to innovative cancer treatments and therapies.
How does ATG-022 target tumors?
ATG-022 operates by specifically targeting the overexpressed Claudin 18.2 protein commonly found on the surface of certain tumor types, enabling better treatment efficacy.
